Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paritaprevir
- Development stage
- Phase 4
- Lead developer
- AbbVie
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Paritaprevir is a direct acting antiviral agent classified as an acylsulfonamide inhibitor of the hepatitis C virus (HCV) NS3/4A serine protease. It is used in combination with other antiviral agents, such as ombitasvir and ritonavir (with or without dasabuvir), for the treatment of chronic hepatitis C infection, particularly HCV genotype 1. Paritaprevir inhibits viral replication by blocking the activity of the NS3/4A protease, which is essential for processing and maturation of viral proteins. The drug was developed to improve sustained virologic response rates and reduce resistance compared to older therapies. Paritaprevir-containing regimens have demonstrated high efficacy in clinical trials, achieving SVR rates around 95% in genotype 1 patients[1][5][7]. It was a component of fixed-dose combinations such as Viekira Pak and Technivie; both products have since been discontinued but were not withdrawn due to safety or efficacy concerns[5].
- Brand names
- Viekira PakTechnivieHolkira Pak
- Other names
- Veruprevir
02
Targets
NS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on paritaprevir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paritaprevir.